# SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

> **NCT06767007** · PHASE2 · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 31 (estimated)

## Conditions studied

- Unresectable Locally Recurrent Rectal Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)
- **DRUG:** PD1
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06767007
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767007, "SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06767007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*